Join Us in Ending Diabetes

We have a clear path forward. We need strategic investment to move from lab to human trials and beyond.

Phase 1:

$10–$20M

Scale up + first-in-human trials (18–24 months)

Phase 2:

$10–$20M

Second-in-human trials

Current status:
Foundational investors are on board. The University Hospital Foundation has 7-figure commitments pending.

Phase 3:

$50–$100M

Commercialization and mass scale

Capital Now = A Cure Within Reach

Without investment, we will not progress. Capital now funds:

GMP manufacturing scale-up

First-in-human clinical trials

Regulatory approval pathways

Moving from lab to practical cure

This is not just an investment in a company. This is an investment in life for 589 million people.

One Breakthrough, Multiple Futures

DiaCell’s autologous iPSC process is transferable, offering potential for personalized cures beyond diabetes:

Cardiac disease (cardiomyocytes for heart failure)

Parkinson's disease (dopaminergic neurons)

Other conditions where the body's own cells can become the cure

The fundamental advantage—patient’s own cells = limited immunosuppression—applies regardless of target cell type.

The Window Is Open

Research has reached proof of concept
Timeline to human trials is within 18–24 months
Competitors are accelerating—but our approach is medically superior
Foundational investors are committed
The current political environment favours Canadian-based research

Let’s Start a Conversation

Or contact us directly: info@diacell.com

Join Us in Ending Diabetes

Phase 1:

$10–$20M

Phase 2:

$10–$20M

Phase 3:

$50–$100M

Capital Now = A Cure Within Reach

GMP manufacturing scale-up

First-in-human clinical trials

Regulatory approval pathways

Moving from lab to practical cure

This is not just an investment in a company. This is an investment in life for 589 million people.

One Breakthrough, Multiple Futures

Cardiac disease (cardiomyocytes for heart failure)

Parkinson's disease (dopaminergic neurons)

Other conditions where the body's own cells can become the cure

The fundamental advantage—patient’s own cells = limited immunosuppression—applies regardless of target cell type.

The Window Is Open

Research has reached proof of concept

Timeline to human trials is within 18–24 months

Competitors are accelerating—but our approach is medically superior

Foundational investors are committed

The current political environment favours Canadian-based research

Let’s Start a Conversation